Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

PSMA uptake on [68Ga]-PSMA-11-PET/CT positively corrects with prostate cancer aggressiveness.

Chen M, Qiu X, Zhang Q, Zhang C, Zhou Y, Zhao X, Fu Y, Wang F, Guo H.

Q J Nucl Med Mol Imaging. 2019 Jul 30. doi: 10.23736/S1824-4785.19.03172-8. [Epub ahead of print]

PMID:
31359744
2.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
3.

68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.

Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.

Ann Nucl Med. 2019 Jul 23. doi: 10.1007/s12149-019-01387-0. [Epub ahead of print]

PMID:
31338731
4.

Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer.

Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, Makowski MR, Brenner W, Prasad V.

J Nucl Med. 2018 Feb;59(2):238-243. doi: 10.2967/jnumed.117.195172. Epub 2017 Aug 3.

5.

68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer.

von Klot CJ, Merseburger AS, Böker A, Schmuck S, Ross TL, Bengel FM, Kuczyk MA, Henkenberens C, Christiansen H, Wester HJ, Solass W, Lafos M, Derlin T.

Nucl Med Mol Imaging. 2017 Dec;51(4):314-322. doi: 10.1007/s13139-017-0476-7. Epub 2017 Mar 7.

6.

68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.

Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF.

Clin Nucl Med. 2018 Dec;43(12):e422-e427. doi: 10.1097/RLU.0000000000002289.

PMID:
30273204
7.

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949. doi: 10.1007/s00259-017-3631-6. Epub 2017 Jan 31.

PMID:
28138747
8.

PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.

Verburg FA, Pfister D, Drude NI, Mottaghy FM, Behrendt FF.

Nuklearmedizin. 2017;56(6):225-232. doi: 10.3413/Nukmed-0917-17-07. Epub 2018 Jan 11.

PMID:
29044297
9.

The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.

Yilmaz U, Komek H, Can C, Altindag S.

Ann Nucl Med. 2019 Aug;33(8):545-553. doi: 10.1007/s12149-019-01360-x. Epub 2019 May 8.

PMID:
31069696
10.

68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.

Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1862-1872. doi: 10.1007/s00259-018-4042-z. Epub 2018 May 3.

PMID:
29725716
11.

Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.

Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):70-83. doi: 10.1007/s00259-015-3206-3. Epub 2015 Oct 28.

PMID:
26508290
12.

Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.

Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T.

J Nucl Med. 2017 Dec;58(12):1962-1968. doi: 10.2967/jnumed.117.193581. Epub 2017 May 18.

13.

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison.

Zamboglou C, Schiller F, Fechter T, Wieser G, Jilg CA, Chirindel A, Salman N, Drendel V, Werner M, Mix M, Meyer PT, Grosu AL.

Theranostics. 2016 Jun 18;6(10):1619-28. doi: 10.7150/thno.15344. eCollection 2016.

14.

Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.

BJU Int. 2017 Feb;119(2):209-215. doi: 10.1111/bju.13540. Epub 2016 Jun 18.

15.

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.

Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O'Neill G, Horvath L, Chalasani V, Stricker P, Joshua AM.

J Nucl Med. 2019 Jul;60(7):950-954. doi: 10.2967/jnumed.118.223099. Epub 2018 Dec 14.

PMID:
30552200
16.

Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms.

Zhang J, Shao S, Wu P, Liu D, Yang B, Han D, Li Y, Lin X, Song W, Cao M, Zhang J, Kang F, Qin W, Wang J.

Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):908-920. doi: 10.1007/s00259-018-4255-1. Epub 2019 Jan 11.

PMID:
30635755
17.

Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.

Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug AR.

Prostate. 2015 Nov;75(15):1760-7. doi: 10.1002/pros.23061. Epub 2015 Aug 18.

PMID:
26282590
18.

Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.

Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M.

J Nucl Med. 2017 Jul;58(7):1081-1087. doi: 10.2967/jnumed.116.184457. Epub 2017 Feb 16.

19.

(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.

Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1288-99. doi: 10.1007/s00259-015-3302-4. Epub 2016 Jan 12.

PMID:
26753602
20.

qPSMA: a semi-automatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT.

Gafita A, Bieth M, Kroenke M, Tetteh G, Guenther E, Menze B, Weber WA, Eiber M.

J Nucl Med. 2019 Mar 8. pii: jnumed.118.224055. doi: 10.2967/jnumed.118.224055. [Epub ahead of print]

PMID:
30850484

Supplemental Content

Support Center